Meadhbh McCall appointed as Clinical Research Operations Manager

with No Comments

Oxford 29th August 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced today the appointment of Meadhbh McCall as Clinical Research Operation Manager (CROM). Meadhbh has extensive experience in conducting clinical trials and most recently worked as Senior Clinical Research Associate for Pharm-Olam performing site management and monitoring Phase I and Phase II clinical trials, ensuring their conduct is in accordance with the approved protocol, GCP and international clinical trial regulations.
“We are very pleased to be appointing Meadhbh to this key position as we build our clinical operations capability to advance CXD101 into Phase 2 trials in combination with immune-oncology agents. Meadhbh has wide experience in conducting clinical trials in the UK and internationally and a great track record in delivering clinical trials in oncology to time and budget” said Dr John Whittaker, Chief Operations Officer of Celleron. ‘Her experience with CROs will be especially valuable as we move forward trials of CXD101, our novel dual action HDAC inhibitor, in colorectal cancer and in hepatocellular carcinoma’.
Prior to working for Phar-Olam Meadhbh McCall was a Senior Clinical Research Associate at AbbVie in Ireland conducting international clinical trials in oncology and immunology. Before joining AbbVie she worked for PSI-CRO from October 2010–May 2014 as a Clinical Research Associate in oncology following on from a year working in OCTO, the clinical operations group in the Department of Oncology at the University of Oxford. Meadhbh has a MSc. through Research in Clinical Pharmacology from the Royal College of Surgeons in Ireland and a BA (Mod.) in Medicinal Chemistry from Trinity College at the University of Dublin in Ireland.

 

About Celleron Therapeutics

Celleron Therapeutics, based on the Oxford Science Park, UK, is a drug development company focussed on precision medicine for cancer. It is a spin-out of Oxford University and has secured a number of exclusive licence agreements with pharmaceutical companies, including Astra Zeneca. Celleron’s precision medicine approach is supported by a companion diagnostic biomarker platform, which allows new drugs to be tailored to responsive tumours. Celleron has two Phase 2 clinical assets: CXD101 is a novel dual mechanism HDAC inhibitor which has unique immuno-modulatory effects in tumour cells, and CXD201 represents a new type of topoisomerase inhibitor.